Logo image
Radioresistance in Glioblastoma and the Development of Radiosensitizers
Journal article   Open access   Peer reviewed

Radioresistance in Glioblastoma and the Development of Radiosensitizers

Md Yousuf Ali, Claudia R. Oliva, Abu Shadat M. Noman, Bryan G. Allen, Prabhat C. Goswami, Yousef Zakharia, Varun Monga, Douglas R. Spitz, John M. Buatti and Corinne E. Griguer
Cancers, Vol.12(9), pp.1-29
09/01/2020
DOI: 10.3390/cancers12092511
PMCID: PMC7564557
PMID: 32899427
url
https://doi.org/10.3390/cancers12092511View
Published (Version of record) Open Access

Abstract

Simple Summary Numerous mechanisms of glioblastoma (GBM) radioresistance have been identified but have not yet resulted in development of effective radiosensitizer that can increase the efficacy of radiotherapy. In this review, the authors review the mechanisms of GBM radioresistance along with current status of radiation treatment and imaging techniques used in GBM diagnosis and radiotherapy. In addition, they summarize the current GBM radiosensitizers that are being investigated or enrolled in clinical trials. This review emphasizes on the importance of developing an effective radiosensitizers to increase the outcome of GBM radiotherapy. The authors highlight the importance of discovering of novel mechanism(s) of GBM radioresistance that will lead in developing an effective radiosensitizer. Ionizing radiation is a common and effective therapeutic option for the treatment of glioblastoma (GBM). Unfortunately, some GBMs are relatively radioresistant and patients have worse outcomes after radiation treatment. The mechanisms underlying intrinsic radioresistance in GBM has been rigorously investigated over the past several years, but the complex interaction of the cellular molecules and signaling pathways involved in radioresistance remains incompletely defined. A clinically effective radiosensitizer that overcomes radioresistance has yet to be identified. In this review, we discuss the current status of radiation treatment in GBM, including advances in imaging techniques that have facilitated more accurate diagnosis, and the identified mechanisms of GBM radioresistance. In addition, we provide a summary of the candidate GBM radiosensitizers being investigated, including an update of subjects enrolled in clinical trials. Overall, this review highlights the importance of understanding the mechanisms of GBM radioresistance to facilitate the development of effective radiosensitizers.
Life Sciences & Biomedicine Oncology Science & Technology

Details

Metrics

Logo image